Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/28/2026

1. NVDA
2. USO
3. BSP
4. MPLT
5. ITG
6. CAPR
7. SPY
8. XFLT
9. HCA
10. CHTR

Go back to Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
(NASDAQ: DARE) Delayed: 1.32 +0.04 (3.13%)
Previous Close $1.28    52 Week High $ 
Open $1.28    52 Week Low $ 
Day High $1.35    P/E N/A 
Day Low $1.28    EPS $ 
Volume 168,057